Mitochem Therapeutics

small molecules, mitochondrial dysfunction, cellular metabolism

modulatingsmall molecule

mitocheminc.com·Charleston, South Carolina, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-U2WK

Projects

MC16 mitochondrial biogenesis program

preclinical

drug program · medium

Induce mitochondrial biogenesis to mitigate kidney disease caused by acute kidney injury and diabetic kidney disease.

Novel oxindole small molecule evaluated in rabbit renal proximal tubule cells, mice, and mouse models of acute kidney injury and diabetic kidney disease; activates the PI3K-AKT-eNOS-FOXO1 axis and induces mitochondrial biogenesis.

2025 publication reported in vitro and mouse-model evaluation of MC16 in acute and diabetic nephropathy.

MC16 induced mitochondrial biogenesis, altered the renal cortical metabolome, accelerated renal recovery after acute kidney injury, reduced vascular permeability, diminished mitochondrial dysfunction, decreased diabetes-induced renal swelling, improved renal and mitochondrial function, and reduced interstitial fibrosis in diabetic kidney disease mouse models.

Mitochondrial dysfunction small-molecule neurodegeneration program

undisclosed

drug program · medium

Restore cellular metabolism in neurodegenerative disease by targeting mitochondrial dysfunction, described as an early and fundamental driver of neurodegeneration.

Small-molecule therapeutics targeting mitochondrial dysfunction and cellular metabolism.

Company site states focus on small molecules for neurodegenerative disease and lists a pipeline/indications page, but no specific pipeline asset is supplied.

Mitochondria-protective retinal degeneration small molecules

preclinical

drug program · medium

Protect mitochondrial function under metabolic stress and slow photoreceptor cell loss in retinal degeneration models.

Screened a 50,000-compound drug-like small-molecule library for protection against calcium-induced mitochondrial capacity loss, then evaluated hits with respirometry and retinal explants from rd1 mice.

2016 publication identified two molecules that protected mitochondria and attenuated photoreceptor loss in retinal degeneration models.

Two molecules protected against metabolic-stress-induced mitochondrial capacity loss, blocked mitochondrial fragmentation in 661W cells exposed to calcium ionophore or tert-butylhydroperoxide, and attenuated photoreceptor cell loss in rd1 retinal explants.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

MC16 mitochondrial biogenesis program

preclinical

drug program · medium

Induce mitochondrial biogenesis to mitigate kidney disease caused by acute kidney injury and diabetic kidney disease.

2025 publication reported in vitro and mouse-model evaluation of MC16 in acute and diabetic nephropathy.

Mitochondrial dysfunction small-molecule neurodegeneration program

undisclosed

drug program · medium

Restore cellular metabolism in neurodegenerative disease by targeting mitochondrial dysfunction, described as an early and fundamental driver of neurodegeneration.

Small-molecule therapeutics targeting mitochondrial dysfunction and cellular metabolism.

Company site states focus on small molecules for neurodegenerative disease and lists a pipeline/indications page, but no specific pipeline asset is supplied.

Mitochondria-protective retinal degeneration small molecules

preclinical

drug program · medium

Protect mitochondrial function under metabolic stress and slow photoreceptor cell loss in retinal degeneration models.

2016 publication identified two molecules that protected mitochondria and attenuated photoreceptor loss in retinal degeneration models.